Comparison between insulin tolerance test, growth hormone (GH)-releasing hormone (GHRH), GHRH plus acipimox and GHRH plus GH-releasing peptide-6 for the diagnosis of adult GH deficiency in normal subjects, obese and hypopituitary patients
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: It has been gradually realized that GH may have important physiological functions in adult humans. The biochemical diagnosis of adult GHD is established by provocative testing of GH secretion. The insulin-tolerance test (ITT) is the best validated. The ITT has been challenged because of its low degree of reproducibility and lack of normal range, and is contra-indicated in common clinical situations. Furthermore, in severely obese subjects the response to the ITT frequently overlaps with those found in non-obese adult patients with GHD. DESIGN: The aim of the present study was to evaluate the diagnostic capability of four different stimuli of GH secretion: ITT, GHRH, GHRH plus acipimox (GHRH+Ac), and GHRH plus GHRP-6 (GHRH+GHRP-6), in two pathophysiological situations: hypopituitarism and obesity, and normal subjects. METHODS: Eight adults with hypopituitarism (four female, four male) aged 41-62 Years (48.8+/-1.4 Years), ten obese normal patients (five female, five male) aged 38-62 Years (48.1+/-2.5 Years), with a body mass index of 34.2+/-1.2 kg/m(2), and ten normal subjects (five female, five male) aged 33-62 Years (48.1+/-2.8 Years) were studied. Four tests were performed on each patient or normal subject: An ITT (0.1 U/kg, 0.15 U/kg for obese, i.v., 0 min), GHRH (100 microg, i.v., 0 min), GHRH (100 microg, i.v., 0 min) preceded by acipimox (250 mg, orally, at -270 min and -60 min) (GHRH+Ac); and GHRH (100 microg, i.v., 0 min) plus GHRP-6 (100 microg, i.v., 0 min) (GHRH+GHRP-6). Serum GH was measured by radioimmunoassay. Statistical analyses were performed by Wilcoxon rank sum and by Mann-Whitney tests. RESULTS: After the ITT the mean peak GH secretion was 1.5+/-0.3 microg/l for hypopituitary, 10.1+/-1.7 microg/l (P<0.05 vs hypopituitary) for obese and 17.8+/-2.0 microg/l (P<0.05 vs hypopituitary) for normal. GHRH-induced GH secretion was 2+/-0.7 microg/l for hypopituitary, 3.9+/-1.2 microg/l (P=NS vs hypopituitary) for obese and 22.2+/-3.8 microg/l (P<0.05 vs hypopituitary) for normal. After GHRH+Ac, mean peak GH secretion was 3.3+/-1.4 microg/l for hypopituitary, 14.2+/-2.7 microg/l (P<0.05 vs hypopituitary) for obese and 35.1+/-5.2 microg/l (P<0.05 vs hypopituitary) for normal. GHRH+GHRP-6 induced mean peak GH secretion of 4.1+/-0.9 microg/l for hypopituitary, 38.5+/-6.5 microg/l (P<0.05 vs hypopituitary) for obese and 68.1+/-5.5 microg/l (P<0.05 vs hypopituitary) for normal subjects. Individually considered, after ITT, GHRH or GHRH+Ac, the maximal response in hypopituitary patients was lower than the minimal response in normal but higher than the minimal response in obese subjects. In contrast, after GHRH+GHRP-6 the maximal response in hypopituitary patients was lower than the minimal response in normal and obese subjects. CONCLUSIONS: This study suggests that, in this group of patients, although both acipimox and GHRP-6 partially reverse the functional hyposomamotropism of obesity after GHRH, but are unable to reverse the organic hyposomatotropism of hypopituitarism, the combined test GHRH+GHRP-6 most accurately distinguishes both situations, without the side effects of ITT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Salomon, F., Cuneo, R. C., Hesp, R., & Sönksen, P. H. (1989) · New England Journal of Medicine · doi:10.1056/nejm198912283212605 · Cited by 1,326
Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review
Carroll, P. V., Christ the members of Growth Hormon, E. R., Bengtsson, B. Å., Carlsson, L., Christiansen, J. S., Clemmons, D., Hintz, R., Ho, K., Laron, Z., Sizonenko, P., et al. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.2.4594 · Cited by 822 · cited 1×
“On the basis of overwhelming evidence that adults with GHD have impaired health that improves with GH replacement ( 4 ), many countries have already approved such treatment for these patients.”
BackgroundSensitivity and specificity of six tests for the diagnosis of adult GH deficiency
Biller, B. M. K., Samuels, M. H., Zagar, A., Cook, D. M., Arafah, B. M., Bonert, V., Stavrou, S., Kleinberg, D. L., Chipman, J. J., & Hartman, M. L. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.5.8509 · Cited by 423
GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults
Popovic, V., Leal, A., Micic, D., Koppeschaar, H. P., Torres, E., Paramo, C., Obradovic, S., Dieguez, C., & Casanueva, F. F. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02755-0 · Cited by 185
Self-citationRahim, A., Toogood, A. A., & Shalet, S. M. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.00855.x · Cited by 159
Diagnosis of GH Deficiency in Adults--How Good Do the Criteria Need to Be?
Molitch, M. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8339 · Cited by 27
Cited by
Corneli, G., Di Somma, C., Baldelli, R., Rovere, S., Gasco, V., Croce, C. G., Grottoli, S., Maccario, M., Colao, A., Lombardi, G., et al. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01967 · Cited by 317
Qu, X.-D., Gaw Gonzalo, I. T., Al Sayed, M. Y., Cohan, P., Christenson, P. D., Swerdloff, R. S., Kelly, D. F., & Wang, C. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1450 · Cited by 103
“Obesity is known to influence the GH response to the provocative tests (5, 6), but body mass index (BMI) is not considered in the current peak GH cut-off points used in the diagnosis of GHD.”
BackgroundRadiation-induced hypopituitarism
Fernandez, A., Brada, M., Zabuliene, L., Karavitaki, N., & Wass, J. A. H. (2009) · Endocrine-Related Cancer · doi:10.1677/erc-08-0231 · Cited by 84
“As regards the diagnostic value of ITT in obese patients, to our knowledge only a comparative study between 8 hypopituitary patients, 10 obese subjects and 10 normal individuals has been performed (Cordido et al .”
ResultDiagnosis of adult GH deficiency
Gasco, V., Corneli, G., Rovere, S., Croce, C., Beccuti, G., Mainolfi, A., Grottoli, S., Aimaretti, G., & Ghigo, E. (2008) · Pituitary · doi:10.1007/s11102-008-0110-x · Cited by 41
Metadata
- Authors
- Cordido, F., Alvarez-Castro, P., Isidro, M., Casanueva, F., & Dieguez, C.
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-08-01
- Volume
- 149
- Issue
- 2
- Pages
- 117-122
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2153970195
- Cited by
- 62
- References
- 6
- FWCI
- 1.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison between insulin tolerance test, growth hormone (GH)-releasing hormone (GHRH), GHRH plus acipimox and GHRH plus GH-releasing peptide-6 for the diagnosis of adult GH deficiency in normal subjects, obese and hypopituitary patients. https://app.cochat.ai/papers/10.1530/eje.0.1490117
- The paper
- Cordido, F., Alvarez-Castro, P., Isidro, M., Casanueva, F., & Dieguez, C. (2003). Comparison between insulin tolerance test, growth hormone (GH)-releasing hormone (GHRH), GHRH plus acipimox and GHRH plus GH-releasing peptide-6 for the diagnosis of adult GH deficiency in normal subjects, obese and hypopituitary patients. European Journal of Endocrinology. https://doi.org/10.1530/eje.0.1490117
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.